Literature DB >> 28381572

Improving the Expression and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers by Targeted Sequence Changes.

Rajesh P Ringe1, Gabriel Ozorowski2,3, Anila Yasmeen1, Albert Cupo1, Victor M Cruz Portillo1, Pavel Pugach1, Michael Golabek1, Kimmo Rantalainen2,3, Lauren G Holden2,3, Christopher A Cottrell2,3, Ian A Wilson2,3,4, Rogier W Sanders1,5, Andrew B Ward2,3, P J Klasse1, John P Moore6.   

Abstract

Soluble, recombinant native-like envelope glycoprotein (Env) trimers of various human immunodeficiency virus type 1 (HIV-1) genotypes are being developed for structural studies and as vaccine candidates aimed at the induction of broadly neutralizing antibodies (bNAbs). The prototypic design is designated SOSIP.664, but many HIV-1 env genes do not yield fully native-like trimers efficiently. One such env gene is CZA97.012 from a neutralization-resistant (tier 2) clade C virus. As appropriately purified, native-like CZA97.012 SOSIP.664 trimers induce autologous neutralizing antibodies (NAbs) efficiently in immunized rabbits, we sought to improve the efficiency with which they can be produced and to better understand the limitations to the original design. By using structure- and antigenicity-guided mutagenesis strategies focused on the V2 and V3 regions and the gp120-gp41 interface, we developed the CZA97 SOSIP.v4.2-M6.IT construct. Fully native-like, stable trimers that display multiple bNAb epitopes could be expressed from this construct in a stable CHO cell line and purified at an acceptable yield using either a PGT145 or a 2G12 bNAb affinity column. We also show that similar mutagenesis strategies can be used to improve the yields and properties of SOSIP.664 trimers of the DU422, 426c, and 92UG037 genotypes.IMPORTANCE Recombinant trimeric proteins based on HIV-1 env genes are being developed for future vaccine trials in humans. A feature of these proteins is their mimicry of the envelope glycoprotein (Env) structure on virus particles that is targeted by neutralizing antibodies, i.e., antibodies that prevent cells from becoming infected. The vaccine concept under exploration is that recombinant trimers may be able to elicit virus-neutralizing antibodies when delivered as immunogens. Because HIV-1 is extremely variable, a practical vaccine may need to incorporate Env trimers derived from multiple different virus sequences. Accordingly, we need to understand how to make recombinant trimers from many different env genes. Here, we show how to produce trimers from a clade C virus, CZA97.012, by using an array of protein engineering techniques to improve a prototypic construct. We also show that the methods may have wider utility for other env genes, thereby further guiding immunogen design.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Env trimers; HIV-1 vaccine

Mesh:

Substances:

Year:  2017        PMID: 28381572      PMCID: PMC5446630          DOI: 10.1128/JVI.00264-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

1.  Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop.

Authors:  Penny L Moore; Elin S Gray; Daniel Sheward; Maphuti Madiga; Nthabeleng Ranchobe; Zhong Lai; William J Honnen; Molati Nonyane; Nancy Tumba; Tandile Hermanus; Sengeziwe Sibeko; Koleka Mlisana; Salim S Abdool Karim; Carolyn Williamson; Abraham Pinter; Lynn Morris
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

2.  Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor.

Authors:  Leopold Kong; Bin Ju; Yajing Chen; Linling He; Li Ren; Jiandong Liu; Kunxue Hong; Bin Su; Zheng Wang; Gabriel Ozorowski; Xiaolin Ji; Yuanzi Hua; Yanli Chen; Marc C Deller; Yanling Hao; Yi Feng; Fernando Garces; Richard Wilson; Kaifan Dai; Sijy O'Dell; Krisha McKee; John R Mascola; Andrew B Ward; Richard T Wyatt; Yuxing Li; Ian A Wilson; Jiang Zhu; Yiming Shao
Journal:  Immunity       Date:  2016-04-05       Impact factor: 31.745

3.  Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation.

Authors:  Rajesh P Ringe; Rogier W Sanders; Anila Yasmeen; Helen J Kim; Jeong Hyun Lee; Albert Cupo; Jacob Korzun; Ronald Derking; Thijs van Montfort; Jean-Philippe Julien; Ian A Wilson; Per Johan Klasse; Andrew B Ward; John P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-21       Impact factor: 11.205

Review 4.  A Blueprint for HIV Vaccine Discovery.

Authors:  Dennis R Burton; Rafi Ahmed; Dan H Barouch; Salvatore T Butera; Shane Crotty; Adam Godzik; Daniel E Kaufmann; M Juliana McElrath; Michel C Nussenzweig; Bali Pulendran; Chris N Scanlan; William R Schief; Guido Silvestri; Hendrik Streeck; Bruce D Walker; Laura M Walker; Andrew B Ward; Ian A Wilson; Richard Wyatt
Journal:  Cell Host Microbe       Date:  2012-10-18       Impact factor: 21.023

5.  Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens.

Authors:  Jean-Philippe Julien; Jeong Hyun Lee; Gabriel Ozorowski; Yuanzi Hua; Alba Torrents de la Peña; Steven W de Taeye; Travis Nieusma; Albert Cupo; Anila Yasmeen; Michael Golabek; Pavel Pugach; P J Klasse; John P Moore; Rogier W Sanders; Andrew B Ward; Ian A Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2015-09-08       Impact factor: 11.205

6.  Stable 293 T and CHO cell lines expressing cleaved, stable HIV-1 envelope glycoprotein trimers for structural and vaccine studies.

Authors:  Nancy P Y Chung; Katie Matthews; Helen J Kim; Thomas J Ketas; Michael Golabek; Kevin de Los Reyes; Jacob Korzun; Anila Yasmeen; Rogier W Sanders; Per Johan Klasse; Ian A Wilson; Andrew B Ward; Andre J Marozsan; John P Moore; Albert Cupo
Journal:  Retrovirology       Date:  2014-04-25       Impact factor: 4.602

7.  A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic β-Hairpin Structure.

Authors:  Jeong Hyun Lee; Raiees Andrabi; Ching-Yao Su; Anila Yasmeen; Jean-Philippe Julien; Leopold Kong; Nicholas C Wu; Ryan McBride; Devin Sok; Matthias Pauthner; Christopher A Cottrell; Travis Nieusma; Claudia Blattner; James C Paulson; Per Johan Klasse; Ian A Wilson; Dennis R Burton; Andrew B Ward
Journal:  Immunity       Date:  2017-04-18       Impact factor: 31.745

8.  Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope.

Authors:  Laura K Pritchard; David J Harvey; Camille Bonomelli; Max Crispin; Katie J Doores
Journal:  J Virol       Date:  2015-06-17       Impact factor: 5.103

9.  A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.

Authors:  Rogier W Sanders; Ronald Derking; Albert Cupo; Jean-Philippe Julien; Anila Yasmeen; Natalia de Val; Helen J Kim; Claudia Blattner; Alba Torrents de la Peña; Jacob Korzun; Michael Golabek; Kevin de Los Reyes; Thomas J Ketas; Marit J van Gils; C Richter King; Ian A Wilson; Andrew B Ward; P J Klasse; John P Moore
Journal:  PLoS Pathog       Date:  2013-09-19       Impact factor: 6.823

10.  Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C.

Authors:  P J Klasse; Celia C LaBranche; Thomas J Ketas; Gabriel Ozorowski; Albert Cupo; Pavel Pugach; Rajesh P Ringe; Michael Golabek; Marit J van Gils; Miklos Guttman; Kelly K Lee; Ian A Wilson; Salvatore T Butera; Andrew B Ward; David C Montefiori; Rogier W Sanders; John P Moore
Journal:  PLoS Pathog       Date:  2016-09-14       Impact factor: 6.823

View more
  17 in total

1.  Effects of the SOS (A501C/T605C) and DS (I201C/A433C) Disulfide Bonds on HIV-1 Membrane Envelope Glycoprotein Conformation and Function.

Authors:  Hanh T Nguyen; Nirmin Alsahafi; Andrés Finzi; Joseph G Sodroski
Journal:  J Virol       Date:  2019-05-29       Impact factor: 5.103

2.  Immunization with HIV-1 trimeric SOSIP.664 BG505 or founder virus C (FVCEnv) covalently complexed to two-domain CD4S60C elicits cross-clade neutralizing antibodies in New Zealand white rabbits.

Authors:  Nancy L Tumba; Gavin R Owen; Mark A Killick; Maria A Papathanasopoulos
Journal:  Vaccine X       Date:  2022-09-30

3.  High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity.

Authors:  Ian Setliff; Andrea R Shiakolas; Kelsey A Pilewski; Amyn A Murji; Rutendo E Mapengo; Katarzyna Janowska; Simone Richardson; Charissa Oosthuysen; Nagarajan Raju; Larance Ronsard; Masaru Kanekiyo; Juliana S Qin; Kevin J Kramer; Allison R Greenplate; Wyatt J McDonnell; Barney S Graham; Mark Connors; Daniel Lingwood; Priyamvada Acharya; Lynn Morris; Ivelin S Georgiev
Journal:  Cell       Date:  2019-11-28       Impact factor: 41.582

4.  A Universal Approach to Optimize the Folding and Stability of Prefusion-Closed HIV-1 Envelope Trimers.

Authors:  Lucy Rutten; Yen-Ting Lai; Sven Blokland; Daphne Truan; Ilona J M Bisschop; Nika M Strokappe; Annemart Koornneef; Danielle van Manen; Gwo-Yu Chuang; S Katie Farney; Hanneke Schuitemaker; Peter D Kwong; Johannes P M Langedijk
Journal:  Cell Rep       Date:  2018-04-10       Impact factor: 9.423

5.  Mining HIV controllers for broad and functional antibodies to recognize and eliminate HIV-infected cells.

Authors:  Evan D Rossignol; Anne-Sophie Dugast; Hacheming Compere; Christopher A Cottrell; Jeffrey Copps; Shu Lin; Deniz Cizmeci; Michael S Seaman; Margaret E Ackerman; Andrew B Ward; Galit Alter; Boris Julg
Journal:  Cell Rep       Date:  2021-05-25       Impact factor: 9.423

6.  Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers.

Authors:  Rajesh P Ringe; Gabriel Ozorowski; Kimmo Rantalainen; Weston B Struwe; Katie Matthews; Jonathan L Torres; Anila Yasmeen; Christopher A Cottrell; Thomas J Ketas; Celia C LaBranche; David C Montefiori; Albert Cupo; Max Crispin; Ian A Wilson; Andrew B Ward; Rogier W Sanders; P J Klasse; John P Moore
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

7.  HIV-1 vaccine design through minimizing envelope metastability.

Authors:  Linling He; Sonu Kumar; Joel D Allen; Deli Huang; Xiaohe Lin; Colin J Mann; Karen L Saye-Francisco; Jeffrey Copps; Anita Sarkar; Gabrielle S Blizard; Gabriel Ozorowski; Devin Sok; Max Crispin; Andrew B Ward; David Nemazee; Dennis R Burton; Ian A Wilson; Jiang Zhu
Journal:  Sci Adv       Date:  2018-11-21       Impact factor: 14.136

8.  Optimizing the production and affinity purification of HIV-1 envelope glycoprotein SOSIP trimers from transiently transfected CHO cells.

Authors:  Albert Cupo; Victor M Cruz Portillo; Paul Gelfand; Anila Yasmeen; P J Klasse; John P Moore
Journal:  PLoS One       Date:  2019-04-08       Impact factor: 3.240

9.  Neutralizing Antibodies Induced by First-Generation gp41-Stabilized HIV-1 Envelope Trimers and Nanoparticles.

Authors:  Sonu Kumar; Xiaohe Lin; Timothy Ngo; Benjamin Shapero; Cindy Sou; Joel D Allen; Jeffrey Copps; Lei Zhang; Gabriel Ozorowski; Linling He; Max Crispin; Andrew B Ward; Ian A Wilson; Jiang Zhu
Journal:  mBio       Date:  2021-06-22       Impact factor: 7.867

10.  cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate.

Authors:  Antu K Dey; Albert Cupo; Gabriel Ozorowski; Vaneet K Sharma; Anna-Janina Behrens; Eden P Go; Thomas J Ketas; Anila Yasmeen; Per J Klasse; Eddy Sayeed; Heather Desaire; Max Crispin; Ian A Wilson; Rogier W Sanders; Thomas Hassell; Andrew B Ward; John P Moore
Journal:  Biotechnol Bioeng       Date:  2017-12-11       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.